

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

5 Applicant : Henry Lardy, et al.
Application No. : 09/675,323
Filed : September 28, 2000
Title : Therapeutic Treatment of Androgen Driven Conditions
Examiner : Elli Peselev
TC/A.U. : 1623

10 Confirmation No. : 2363
Docket No. : 208.3
Customer No. : 26551

15 Correction of Inventorship under 37 C.F.R. 1.48(a)

20 Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

25 Applicants submit this paper in to correct an error in the inventorship for this application.

Applicants request correction of the inventors that are named in this application to include Dr. James M. Frincke in addition to the originally named inventors, Dr. Henry Lardy and Dr. Padma Marwa.

30 This request is accompanied by a statement from the added inventor, Dr. Frincke, that the error in inventorship occurred without deceptive intention on his part.

This request is also accompanied by a declaration under 37 CFR § 1.63 signed by all three inventors, the required fee under 37 CFR § 1.17(i) and a statement by the assignee of this patent application consenting to this change in inventorship.

Respectfully submitted,

Date: August 2, 2007

/ Daryl D. Muenchau /

40 Vice President, Intellectual Property
Hollis-Eden Pharmaceuticals, Inc.
4435 Eastgate Mall, Suite 400
San Diego, California 92121
Phone: 858-320-2569

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

5 Applicant : Henry Lardy, et al.
Application No. : 09/675,323
Filed : September 28, 2000
Title : Therapeutic Treatment of Androgen Driven Conditions
Examiner : Elli Peselev
TC/A.U. : 1623

10 Confirmation No. : 2363
Docket No. : 208.3
Customer No. : 26551

15

Inventor Statement Under 37 C.F.R. 1.48(a)(2) to
Support Amendment of Inventorship

20 Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


25 Dear Sir:

This paper is submitted to support amendment of the inventorship for this application.

The error in the inventorship whereby I was omitted as a named inventor of this patent application occurred without any deceptive intention on my part.

30

Respectfully submitted,



James M. Frincke

35

Date: June 6, 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

5 Applicant : Henry Lardy, et al.
Application No. : 09/675,323
Filed : September 28, 2000
Title : Therapeutic Treatment of Androgen Driven Conditions
Examiner : Elli Peselev
TC/A.U. : 1623

10 Confirmation No. : 2363
Docket No. : 208.3
Customer No. : 26551

15 Assignee statement of consent to correction of
inventorship under 37 CFR §§ 1.48(a)(5) and 3.73(b)(2)

20 Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir,

25 This paper is submitted by EFS-web submission and accompanies a request
under 37 CFR § 1.48(a) to correct the inventorship in this patent application. Hollis-Eden
Pharmaceuticals, Inc. is the assignee of this patent application as evidenced by the
assignment that is on file in the USPTO at Reel 011469, Frame 0149.

30 Hollis-Eden Pharmaceuticals, Inc. consents to the change in named inventors for
this application by adding Dr. James M. Frincke as a co-inventor with the originally
named inventors, Dr. Henry Lardy and Dr. Padma Marwa.

The undersigned is authorized to act on behalf of the assignee in this matter.

35 Date: August 2, 2007

Respectfully submitted,
/ Daryl D. Muenchau /
Daryl D. Muenchau, Reg. No. 36,616
Vice President, Intellectual Property
Hollis-Eden Pharmaceuticals, Inc.
4435 Eastgate Mall, Suite 400
San Diego, CA 92121
Phone: 858-320-2569

40